Exclusive

glass vials/conveyor belt

Exclusive

Gilead ups its donation of the Covid-19 drug remdesivir for U.S. hospitals

By Eric Boodman

Dr. Michelle McMurry-Heath

Exclusive

Biotech’s new chief lobbyist says she’s a social justice advocate. Will the industry walk the walk?

By Nicholas Florko and Matthew Herper

Parkinson's cell transplant

Exclusive

A secret experiment revealed: In a medical first, doctors treat Parkinson’s with a novel brain cell transplant

By Sharon Begley

NY phlebotomist

Exclusive

Inside the NIH’s controversial decision to stop its big remdesivir study

By Matthew Herper

Virus Outbreak Nebraska Testing

Exclusive

Many states are far short of Covid-19 testing levels needed for safe reopening, new analysis shows

By Sharon Begley

Rick Bright

Exclusive

Director of U.S. agency key to vaccine development leaves role suddenly amid coronavirus pandemic

By Nicholas Florko

remdesivir antiviral drug

Exclusive

Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment

By Adam Feuerstein and Matthew Herper

abbott labs/trump

Exclusive

Rapid coronavirus test, commonly used in U.S., may miss infections in some situations

By Matthew Herper

licensing agreement UCSF & Google_1

Exclusive

Contract offers unprecedented look at Google deal to obtain patient data from the University of California

By Rebecca Robbins

Robert Redfield

Exclusive

CDC director: More person-to-person coronavirus infections in U.S. likely, but containment still possible

By Helen Branswell

Exclusive

This VC firm once pledged to never invest in health care. Now it’s launching its third life sciences fund

By Erin Brodwin

Mike Ryan

Exclusive

Top WHO official says it’s not too late to stop the new coronavirus outbreak

By Helen Branswell

Big data concept illustration

Exclusive

Medical data startup Syapse cuts 10% of workforce as it prioritizes data analytics and insights

By Rebecca Robbins

headquarters of Verily Life Sciences

Exclusive

Verily tangos at JPM with a health tech partner — and steps on a few toes

By Erin Brodwin

SHATTERED DIGIPILL

Exclusive

A forerunner in ‘smart pills’ adopts a new tack as key pharma partnership unravels

By Rebecca Robbins

OC Phases

Exclusive

The history of OxyContin, told through unsealed Purdue documents

By Shraddha Chakradhar and Casey Ross

Purdue docs

Exclusive

Purdue’s Richard Sackler proposed plan to play down OxyContin risks, and wanted drug maker feared ‘like a tiger,’ files show

George Church

Exclusive

Citing ‘nerd tunnel vision,’ biologist George Church apologizes for contacts with Jeffrey Epstein

By Sharon Begley

U.S. Capitol

Exclusive

PhRMA’s top lobbyist will leave at the end of August

By Nicholas Florko

Dr. Feng Zhang Broad Inst

Exclusive

The latest CRISPR patent fight is on. So is the mudslinging

By Sharon Begley

MilliporeSigma sign

Exclusive

Fight for coveted CRISPR patents gets knottier, as MilliporeSigma makes new claims

By Sharon Begley

Sean Parker reflection

Heavyweights

Billionaire Sean Parker is nerding out on cancer research. Science has never seen anyone quite like him

By Rebecca Robbins

Jennifer Doudna - Genome Editing Conference

Exclusive

GSK partners with CRISPR pioneer Doudna to search for new drugs

By Matthew Herper

Al Sandrock Biogen

Exclusive

One of the world’s best drug hunters went after Alzheimer’s. Here’s how he lost

By Matthew Herper

Ubiome Kit

Business

Troubled microbiome startup uBiome to lay off some employees, refund payments from federal insurers

By Rebecca Robbins

Spina Bifida

Exclusive

‘She’s wiggling her toes’: New fetal surgery for spina bifida may be safer for both baby and mom

By Usha Lee McFarling

Exclusive

Novartis may be close to settling a kickback case on the eve of a trial

By Ed Silverman

Vacuum tubes for blood analysis

Exclusive

New documents reveal Third Rock Ventures is set to launch a cancer diagnostics company

By Kate Sheridan

Exclusive

IBM halting sales of Watson AI tool for drug discovery amid sluggish growth